Logo

EMCURE PHARMACEUTICALS L Share Price

NSE: EMCURE
|
Pharmaceuticals
₹ 1,838.10
-₹18.40 (-0.99%)
1D
Last updated 03 Jul, 2026, 15:29 IST

EMCURE PHARMACEUTICALS L Share Price Today

As of 5 Jul 2026, EMCURE PHARMACEUTICALS L share price is ₹1,838.10. The stock opened at ₹1,856.50, compared to its previous close of ₹1,856.50. During today's trading session, EMCURE PHARMACEUTICALS L share price moved in the range of ₹1,830.20 to ₹1,860.00, with an average price of ₹1,845.10 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,228.90 and a high of ₹1,944.00. On the performance front, EMCURE PHARMACEUTICALS L share price has increased by 28.53% over the last six months and is up 43.70% on a year-on-year basis.

₹1,830.20
0.99% down today
₹1,860.00
1D LOW
1D HIGH

EMCURE PHARMACEUTICALS L Returns Calculator

Open
₹1,856.50
High
₹1,860.00
Low
₹1,830.20
Prev. close
₹1,856.50
Circuit
L
H
₹1,655.20
₹2,023.00
52-week
L
H
₹1,228.90
₹1,944.00

EMCURE PHARMACEUTICALS L Shareholder Returns

EMCURE PHARMACEUTICALS L Share Price History

Mkt Cap Cr
35,178.10
P/E
37.38
P/B
7.11
ROE
18.67%
D/E
0.43
ROCE
21.76%
Div. Yield
0.19%
EPS(TTM)
38.67
Turnover
1.13
EV/EBITDA
19.58
Net Margin
0.00%
Op. Margin
0.00%
ROA
9.79%
Quick Ratio
0.00
Curr. Ratio
1.98
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Emcure Pharma outperforming all market indices
Step 3 of 5
Valuation
Fairly Valued
Emcure Pharma appears to be fairly valued compared to its peers
Step 5 of 5
Earnings
Excellent
Emcure Pharma revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,49,048.0039.025.3713.74%0.6117.33%93.240.85%0.5610.90
Divis Laboratories1,77,179.0069.0010.5715.32%0.0019.56%629.490.45%0.5898.19
Torrent Pharmaceuticals1,57,804.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,17,642.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Dr. Reddy's Laboratories1,12,368.0027.032.9711.07%0.1812.54%375.780.59%0.6338.68
Zydus Lifesciences1,10,651.0021.604.0818.59%0.3117.35%235.250.09%0.3935.38
Lupin1,09,676.0020.484.8923.76%0.0424.88%659.050.75%0.61129.18
Mankind Pharma1,02,729.0053.006.3011.74%0.3413.13%397.020.04%0.5449.37
Aurobindo Pharma90,608.0025.872.399.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,398.9060.2610.1018.21%0.4516.70%10.190.20%0.9713.72

EMCURE PHARMACEUTICALS L Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹7,896.00₹6,658.25₹5,985.81₹5,855.39
Other Income₹72.79₹56.99₹45.91₹63.47
Total Revenue₹7,968.78₹6,715.24₹6,031.72₹5,918.86
Total Expenses₹6,987.06₹5,978.08₹5,278.36₹4,946.31
Profit Before Tax₹971.35₹727.23₹747.22₹972.55
Tax₹263.88₹199.65₹185.37₹269.99
Profit After Tax₹707.47₹527.58₹561.85₹702.56
EPS - Basic₹36.43₹27.54₹29.42₹36.62
EPS - Diluted₹36.43₹27.54₹29.42₹36.62

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹971.35₹727.23₹747.22₹972.55
Income before WC changes₹1,522.86₹1,270.38₹1,239.56₹1,371.29
Change in Assets-₹599.85-₹166.98-₹277.81-₹603.40
Change in Liabilities₹175.56₹217.49-₹14.42₹311.49
Change in WC-₹424.30₹50.52-₹292.24-₹291.91
Cash flow from Operations₹851.71₹1,097.24₹746.85₹768.21
Cash flow from Investing-₹94.00-₹712.51-₹467.69-₹788.79
Cash flow from Financing-₹813.96-₹164.21-₹145.40-₹151.85
Total Cash Flow-₹56.25₹220.52₹133.77-₹172.44
Cash (Start of the year)₹43.99-₹174.53-₹308.17-₹350.04
Cash (End of the year)-₹14.31₹43.99-₹174.53-₹308.17

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹3,676.86₹3,546.25₹2,836.62₹2,639.37
Current Assets₹4,555.86₹4,259.92₹3,835.91₹3,424.10
Total Assets₹8,232.72₹7,806.16₹6,672.53₹6,063.47
Current Liabilities₹2,668.27₹3,210.47₹3,019.19₹2,964.83
Net Current Asset₹1,887.59₹1,049.44₹816.72₹459.27
Non-Current Liabilities₹922.90₹1,473.93₹1,003.68₹984.50
Equity Capital₹4,641.55₹3,121.77₹2,649.66₹2,114.14
Total Equity & Liabilities₹8,232.72₹7,806.16₹6,672.53₹6,063.47

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹4,381.92₹3,497.66₹3,107.09₹3,387.24
Other Income₹142.48₹138.26₹125.35₹132.68
Total Revenue₹4,524.40₹3,635.91₹3,232.44₹3,519.92
Total Expenses₹4,096.69₹3,426.69₹3,013.95₹2,903.50
Profit Before Tax₹427.71₹199.91₹212.34₹616.42
Tax₹110.58₹39.08₹52.28₹169.61
Profit After Tax₹317.13₹160.83₹160.06₹446.81
EPS - Basic₹16.95₹8.89₹8.85₹24.71
EPS - Diluted₹16.95₹8.89₹8.85₹24.71

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹427.71₹199.91₹212.34₹616.42
Income before WC changes₹711.85₹525.47₹521.55₹881.42
Change in Assets-₹368.39-₹91.66-₹22.13-₹324.96
Change in Liabilities₹280.94₹218.02₹90.49₹41.92
Change in WC-₹87.45₹126.36₹68.37-₹283.04
Cash flow from Operations₹558.29₹584.97₹505.37₹427.71
Cash flow from Investing-₹435.61-₹171.08-₹270.44-₹189.00
Cash flow from Financing-₹49.25-₹287.75-₹54.52-₹342.96
Total Cash Flow₹73.43₹126.15₹180.42-₹309.06
Cash (Start of the year)-₹88.91-₹213.05-₹393.35-₹84.29
Cash (End of the year)-₹17.53-₹88.91-₹213.05-₹393.35

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹2,956.06₹2,633.50₹2,456.44₹2,181.56
Current Assets₹2,460.05₹2,123.43₹2,159.41₹2,141.63
Total Assets₹5,416.11₹4,756.93₹4,615.85₹4,323.18
Current Liabilities₹1,719.16₹2,130.12₹1,996.33₹1,934.06
Net Current Asset₹740.89-₹6.68₹163.07₹207.56
Non-Current Liabilities₹672.59₹691.72₹777.65₹676.59
Equity Capital₹3,024.36₹1,935.10₹1,841.87₹1,712.53
Total Equity & Liabilities₹5,416.11₹4,756.93₹4,615.85₹4,323.18
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1839.1
10
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 10
Buy orders: 0%
Sell orders: 100%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
60.09
Neutral
ATR (14)
57.31
Neutral
STOCH(9,6)
43.33
Neutral
STOCH RSI (14)
51.42
Neutral
ADX(9)
42.79
Bearish
UO(9)
40.5
Neutral
ROC(12)
6
Bullish
WillR(14)
-39.89
Neutral
Period
Simple value
Exponential vaue
5D
1842.4
1840.52
10D
1831.59
1824.45
20D
1780.36
1792.93
50D
1724.65
1727.42
100D
1622.62
1651.45

About EMCURE PHARMACEUTICALS L

EMCURE PHARMACEUTICALS L logo
ISIN
INE168P01015
Sector Market Cap
₹ 35,178.1 Cr

Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.

EMCURE PHARMACEUTICALS L Financial Highlights

  • Revenue: EMCURE PHARMACEUTICALS L reported revenue of ₹9,216.20 crore in FY26 vs ₹7,963.26 crore in FY25. It showed an increase of 15.73% on a yearly basis.
  • Operating Profit: EMCURE PHARMACEUTICALS L reported an operating profit of ₹1,287.14 crore in FY26 vs ₹971.35 crore in FY25. It showed an increase of 32.51% on a year-on-year basis.
  • Net Profit: EMCURE PHARMACEUTICALS L reported a net profit of ₹941.27 crore in FY26 vs ₹707.47 crore in FY25. It showed an increase of 33.05% on a yearly basis.

EMCURE PHARMACEUTICALS L Quarterly Result Highlights

  • EMCURE PHARMACEUTICALS L reported revenue of ₹2,473.69 crore in Mar 2026, compared with ₹2,365.33 crore in Dec 2025, representing an increase of 4.58% on a quarter-on-quarter (QoQ) basis.
  • EMCURE PHARMACEUTICALS L reported an operating profit of ₹341.18 crore in Mar 2026, compared with ₹313.79 crore in Dec 2025, representing an increase of 8.73% on a quarter-on-quarter (QoQ) basis.
  • EMCURE PHARMACEUTICALS L reported a profit of ₹243.74 crore in Mar 2026, compared with ₹231.37 crore in Dec 2025, reflecting an increase of 5.35% on a QoQ basis.
  • The earnings per share (EPS) of EMCURE PHARMACEUTICALS L stood at ₹36.43 during Mar 2026.
Know more
Promoters
77.87%
FII
3.35%
Other DII
1.16%
Retail and other
12.68%
Mutual funds
4.94%
Foreign institutions - FII
Compare against other stocks
EMCURE PHARMACEUTICALS L logo
EMCURE PHARMACEUTICALS L
Pharmaceuticals
Add Stock
Add Another

FAQs on EMCURE PHARMACEUTICALS L Share Price